Physician profile
Mark E Crispin
NPI 1699730705
$6,418.54
in general payments reported to CMS, 2019-2025
12 companies · $71.25 in 2025
The $71.25 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,912 · 2020: $1,402 · 2021: $2,034 · 2022: $249 · 2023: $289 · 2024: $461 · 2025: $71.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $2,624.13 | 2020-2021 | |
| Allergan, INC. | $2,163.75 | 2019-2022 | |
| Mentor Worldwide LLC | $813.64 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Abbvie INC. | $304.46 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Botox |
| Depuy Synthes Sales INC. | $201.75 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.31 | 2024 | Camzyos |
| Davol INC. | $73.24 | 2023 | Phasix Mesh |
| Galderma Laboratories, L.P. | $47.22 | 2020-2023 | |
| Tepha INC | $39.37 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $21.55 | 2019 | |
| Boston Scientific Corporation | $12.56 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $6.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Crispin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.